SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a
SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “abiraterone-like” agent in comparison with placebo — though radiographic progression-free survival was improved. This finding at the 2014 ASCO Genitourinary Cancers Symposium was presented by Robert Dreicer MD from the Taussig Cancer Institute, Cleveland Clinic, in Cleveland Ohio. He discussed the clinical implications and noted that research is making progress in this challenging clinical situation.
CONTACT:
Dr. Robert Dreicer MD
Taussig Cancer Institute
9500 Euclid Avenue/ R35
Cleveland Clinic, Cleveland
OHIO 44195
USA
SOURCE: ASCO Genitourinary Cancers Symposium 2014 San Francisco
e.g. Abstract number: 7^
Abstract Title:
Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).
LINK:
Web link: http://meetinglibrary.asco.org/content/124293-142
Related Episodes
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon